Bertram Scott Sells 217 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) Director Bertram Scott sold 217 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Becton, Dickinson and Company Stock Up 0.3%

Becton, Dickinson and Company stock opened at $177.88 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a 50 day moving average price of $186.77 and a 200 day moving average price of $182.30. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The company has a market capitalization of $50.99 billion, a PE ratio of 31.99, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion for the quarter. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s payout ratio is 71.36%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. SOA Wealth Advisors LLC. lifted its stake in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Activest Wealth Management raised its holdings in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares in the last quarter. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Bell Investment Advisors Inc grew its position in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares during the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. Royal Bank Of Canada cut their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research note on Friday. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $203.27.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.